Jazz Pharmaceuticals plc – (JAZZ) PT Set at $170.00 by Leerink Swann

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) has been given a $170.00 price target by equities research analysts at Leerink Swann in a research report issued to clients and investors on Thursday. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Leerink Swann’s price objective indicates a potential upside of 10.23% from the company’s previous close.

JAZZ has been the subject of a number of other reports. Cantor Fitzgerald reiterated a “buy” rating and issued a $187.00 price objective on shares of Jazz Pharmaceuticals plc – in a report on Thursday, January 12th. Zacks Investment Research cut shares of Jazz Pharmaceuticals plc – from a “hold” rating to a “sell” rating in a report on Thursday, March 2nd. Janney Montgomery Scott upgraded shares of Jazz Pharmaceuticals plc – from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $138.00 to $175.00 in a report on Thursday, April 6th. Guggenheim reiterated a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals plc – in a report on Thursday, February 9th. Finally, Deutsche Bank AG set a $148.00 price objective on shares of Jazz Pharmaceuticals plc – and gave the stock a “buy” rating in a report on Wednesday, February 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and fourteen have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $181.23.

Analyst Recommendations for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)

Shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) opened at 154.22 on Thursday. The stock’s 50 day moving average price is $143.48 and its 200 day moving average price is $123.54. Jazz Pharmaceuticals plc – has a 12-month low of $95.80 and a 12-month high of $160.00. The firm has a market cap of $9.21 billion, a PE ratio of 24.06 and a beta of 1.22.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, February 28th. The specialty pharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $2.65 by $0.74. The business earned $396.62 million during the quarter, compared to the consensus estimate of $398.91 million. Jazz Pharmaceuticals plc – had a return on equity of 30.50% and a net margin of 24.81%. The company’s revenue for the quarter was up 16.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.60 earnings per share. On average, equities research analysts predict that Jazz Pharmaceuticals plc – will post $11.10 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://sportsperspectives.com/2017/04/21/jazz-pharmaceuticals-plc-jazz-given-a-170-00-price-target-by-leerink-swann-analysts-2-updated.html.

In other news, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction dated Tuesday, April 11th. The shares were sold at an average price of $152.12, for a total transaction of $152,120.00. Following the completion of the transaction, the chief executive officer now owns 308,491 shares of the company’s stock, valued at $46,927,650.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Michael Patrick Miller sold 200 shares of the company’s stock in a transaction dated Monday, April 17th. The shares were sold at an average price of $152.56, for a total transaction of $30,512.00. Following the transaction, the senior vice president now directly owns 22,562 shares of the company’s stock, valued at approximately $3,442,058.72. The disclosure for this sale can be found here. Insiders have sold 13,942 shares of company stock valued at $2,098,147 in the last ninety days. 3.90% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Howard Hughes Medical Institute bought a new position in shares of Jazz Pharmaceuticals plc – during the third quarter worth approximately $112,000. Brave Asset Management Inc raised its position in shares of Jazz Pharmaceuticals plc – by 540.0% in the third quarter. Brave Asset Management Inc now owns 960 shares of the specialty pharmaceutical company’s stock worth $117,000 after buying an additional 810 shares in the last quarter. Daiwa Securities Group Inc. raised its position in shares of Jazz Pharmaceuticals plc – by 10.7% in the third quarter. Daiwa Securities Group Inc. now owns 1,550 shares of the specialty pharmaceutical company’s stock worth $188,000 after buying an additional 150 shares in the last quarter. Mn Services Vermogensbeheer B.V. raised its position in shares of Jazz Pharmaceuticals plc – by 2.4% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 1,557 shares of the specialty pharmaceutical company’s stock worth $189,000 after buying an additional 37 shares in the last quarter. Finally, Bridges Investment Management Inc. bought a new position in shares of Jazz Pharmaceuticals plc – during the first quarter worth approximately $208,000. 88.56% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals plc – Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

5 Day Chart for NASDAQ:JAZZ

Receive News & Ratings for Jazz Pharmaceuticals plc - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals plc - and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply